Tuesday, April 11, 2017 3:13:30 PM
There is something important going on with Gilead Sciences, Inc. (NASDAQ:GILD). It is likely telling investors the downtrend is nearing an end and significant upside is on the horizon. Based on what I will explain to all investors, I will be buying Gilead Sciences at $65.75...
The basis for my thesis comes from the way the stock has acted over the last two months. Since early February 2017, Gilead Sciences jumped from multi-year lows, surging 10% in one week. Over the last 7 weeks, the stock has every-so-slowly inched back down. This is a major change in character from a stock that usually collapsed sharply in a week and took 7 weeks to inch back up before its next collapse. In other words, the price action is showing institutional (big money) accumulation. In addition, the valuation is very attractive. Analysts continue to strongly believe Gilead Sciences needs to buy some drug companies and I believe the company has heard them. I am sure acquisitions will be on the horizon as Gilead Sciences is sitting on a huge pile of cash.
Gareth Soloway
InTheMoneyStocks
Recent GILD News
- Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024 • Business Wire • 04/08/2024 08:05:00 PM
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six • Business Wire • 03/28/2024 12:30:00 PM
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program • Business Wire • 03/28/2024 11:00:00 AM
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Gilead Sciences Announces Completion of Acquisition of CymaBay • Business Wire • 03/22/2024 01:18:00 PM
- Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant • Business Wire • 03/18/2024 11:29:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 03/11/2024 12:34:07 PM
- Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer • Business Wire • 03/11/2024 12:24:00 PM
- Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities • Business Wire • 03/06/2024 09:30:00 PM
- Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 • Business Wire • 03/06/2024 03:25:00 PM
- Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers • Business Wire • 03/06/2024 01:00:00 PM
- New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19 • Business Wire • 03/05/2024 09:35:00 PM
- Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health • Business Wire • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:35:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:49:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 09:38:50 PM
- Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. • Business Wire • 02/27/2024 03:00:00 PM
- U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance • Business Wire • 02/26/2024 09:05:00 PM
- Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 • Business Wire • 02/26/2024 01:30:00 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 02/23/2024 11:09:33 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 09:31:04 PM
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 02/20/2024 09:05:00 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 02/14/2024 10:08:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:48:49 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:54:00 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM